2012: Avanafil Approved

On This Day in Health: April 27, 2012

On April 27, 2012, the U.S. Food and Drug Administration approved Stendra, the brand name for avanafil, to treat erectile dysfunction. VIVUS developed the U.S. application for the oral medicine, which had been licensed from Mitsubishi Tanabe Pharma. The decision added an option within an established class of medicines called phosphodiesterase type 5 inhibitors, commonly shortened to PDE5 inhibitors. It was an approval of a new drug, rather than the invention of the entire treatment approach. That distinction places the anniversary in its proper setting: researchers and regulators were assessing another molecule for a condition that already had prescription therapies available.

Erectile dysfunction involves difficulty achieving or maintaining an erection sufficient for sexual activity. The problem can occur alongside diabetes, cardiovascular disease, medication effects and other health concerns. Avanafil acts on a signaling pathway involved in the relaxation of smooth muscle and blood flow. PDE5 inhibition helps preserve the effect of that pathway during sexual stimulation. This mechanism does not mean that the drug produces an automatic response in every circumstance, removes the underlying cause of a patient’s condition or replaces an assessment of general health. Its purpose was to improve erectile function in the setting for which it was tested and approved, with the usual limitations of an individual response to treatment.

The regulatory review included placebo-controlled clinical studies. The FDA’s assessment described pivotal trials in a general erectile dysfunction population and in men with diabetes. Researchers used questionnaires and patient diaries to examine erectile function and the outcomes of attempts at sexual activity. The analyses found improvements with avanafil compared with placebo on the main measures studied. Those comparisons supplied evidence that the medicine’s biological activity translated into a useful clinical effect. They should not be read as proof that it would outperform every other PDE5 inhibitor for every patient. A new approved option can matter because responses, preferences and medical circumstances vary, even when medicines share a broad mechanism.

Safety remained central to the approval. Like other medicines in this class, avanafil could lower blood pressure, and taking it with nitrate medicines could cause an unsafe drop. The review and labeling also addressed interactions and other adverse effects. These conditions of use were part of the treatment’s meaning, not an afterthought to the announcement. April 27 represents an expansion of the choices available for a common condition that can affect relationships and quality of life. The historical significance lies in the combination of a defined pharmacological action, clinical comparison with placebo and a regulatory decision specifying how the medicine could be used. It illustrates incremental medical progress: another tested tool became available, while thoughtful selection and the patient’s broader health continued to shape its role.